<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48686">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02028728</url>
  </required_header>
  <id_info>
    <org_study_id>G1307</org_study_id>
    <nct_id>NCT02028728</nct_id>
  </id_info>
  <brief_title>BIOFLOW III Satellite-Italy</brief_title>
  <official_title>Safety and Performance Registry for an All Comers Patient Population With the Limus Eluting Orsiro Stent Within Daily Clinical Practice III-Italy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik Italia S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik Italia S.p.A.</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal
      Coronary Angioplasty (PTCA) provides high initial procedure success. However, the medium to
      long-term complications range from rather immediate elastic coil or vessel contraction to
      longer processes like smooth muscle cell proliferation and excessive production of extra
      cellular matrix, thrombus formation and atherosclerotic changes like restenosis or
      angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from 30 to
      50%. Such rates of recurrence have serious economic consequences. Bare Metal Stents (BMS),
      designed to address the limitations of PTCA, reduced the angiographic and clinical
      restenosis rates in De Novo lesions compared to PTCA alone and decreased the need for CABG.
      BMS substantially reduced the incidence of abrupt artery closure, but restenosis still
      occurred in about 20 to 40% of cases, necessitating repeat procedures.

      The invention of Drug Eluting Stents (DES) significantly improved on the principle of BMS by
      adding an antiproliferative drug (directly immobilized on the stent surface or released from
      a polymer matrix), which inhibits neontimal hyperplasia. The introduction of DES greatly
      reduced the incidence of restenosis and resulted in better safety profile as compared to BMS
      with systemic drug administration. These advantages and a lower cost compared to surgical
      interventions has made DES an attractive option to treat coronary artery disease.

      Therefore this observational registry has been designed for the clinical evaluation of the
      ORSIRO LESS requiring coronary revascularization with DES. Results will contribute to the
      collection of clinical evidence for the clinical performance and
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Composite of cardiac death, target vessel Q-wave or non Q-wave Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG) and clinically driven Target Lesion Revascularization (TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TLF</measure>
    <time_frame>6 and 18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>6, 12 and 18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical device success</measure>
    <time_frame>Up to discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>Successful delivery and deployment of the investigational stent (s) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% by visual estimation and without use of a device outside the assigned treatment strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical procedural success</measure>
    <time_frame>up to seven days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Successful delivery and deployment of the investigational stent (s) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% by visual estimation and without using any adjunctive device without the occurrence of ischemia-driven major adverse cardiac event during the hospital stay to a maximum of the first seven days post index procedure.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coronary Artery Diseases</condition>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects requiring coronary revascularization with Drug Eluting Stents (DES)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic coronary artery disease

          -  Subject signed informed consent for data release

          -  Subject is geographically stable and willing to participate at all follow up
             assessments

          -  Subject is â‰¥ 18 years of age

        Exclusion Criteria:

          -  Subject did not sign informed consent

          -  Pregnancy

          -  Known intolerance to aspirin, clopidogrel, Ticlopidine, heparin or any other
             anticoagulant/antiplatelet therapy required for PCI, stainless steel, Sirolimus or
             contrast media

          -  Planned surgery within 6 months after PCI unless dual antiplatelet therapy will be
             maintained

          -  Currently participating in another study and primary endpoint not reached yet
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martina Del Maestro, Clinical Specialist VI</last_name>
    <phone>+3902274394200</phone>
    <email>martina.del.maestro@biotronik.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrzia Presbitero, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Patrizia Presbitero, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Conzorciale di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bortone, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Bortone, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Castelfranco</name>
      <address>
        <city>Castelfranco</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Cernetti, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Carlo Cernetti, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Pugliese-Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Ceravolo, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Ceravolo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Anna</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Galli, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Mario Galli, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale F. Veneziale</name>
      <address>
        <city>Isernia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Versaci, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Versaci, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Civile Legnano</name>
      <address>
        <city>Legnano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaldo Poli, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Arnaldo Poli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Bartorelli, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Bartorelli, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico CittÃ  Studi, Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianfranco Aprigliano, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Gianfranco Aprigliano, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Mediterranea</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Briguori, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Carlo Briguori, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnas Ospedale Civico</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amerigo Stabile, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Amerigo Stabile, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossella Fattori, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Rossella Fattori, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Trani, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Carlo Trani, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>European Hospital</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Tomai, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Fabrizio Tomai, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>December 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>International</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Observational registry</keyword>
  <keyword>Orsiro Drug Eluting Stent (DES)</keyword>
  <keyword>Stenting</keyword>
  <keyword>Treatment of coronary artery disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention (PCI)</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Angina</keyword>
  <keyword>Acute Myocardial Infarction (AMI)</keyword>
  <keyword>Small Vessels</keyword>
  <keyword>Chronic Total Occlusion (CTO)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
